Status: Recruiting
Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies
Open-Label Study (Phase Ib) of Type 1 Interferonopathy patients receiving IMSB301 monotherapy.
Participants needed: 6
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: ImmuneSensor Therapeutics Inc.Updated: Jan 23, 2026Locations: 1
Eligibility criteria
First subject must be at least 16 years of age and weighing at least 50 kg. Rema... [+11]
Presence of other significant neurological disorder that is not related to type... [+18]